The US Senate voted 54 to 39 in favor of S 3101, the Medicare Improvements for Patients and Providers Act of 2008. However, that did not achieve the 60 votes needed for cloture. The bill includes pharmacy-related provisions that provide prompt payment of Medicare Part D prescription drug claims and delay the implementation of Medicaid reimbursement cuts for generic prescription medicines.
In response, Bruce Roberts, executive vice president and chief executive of the National Community Pharmacists Association, issued the following statement: "while S3101, the health care bill championed by Senate Finance Committee Chairman Max Baucus (Democrat, Montana) and a majority of the US Senate, did not achieve cloture today, America's 23,000 community pharmacies remain committed to ensuring patients have access to prescription drug services. That outcome can only be achieved by including provisions to speed up the painfully slow payment of Medicare Part D claims and delay utilizing a formula designed to drastically cut reimbursements for Medicaid generic prescription drugs."
He continued by noting that the vote is just the first step in a process that needs to culminate with a health care package which Congress must pass by July 1. "We urge Congress, as it takes the next step, to make sure the pharmacy provisions are included. It is our members' intention to continue weighing in on this critical debate that will literally determine the fate of patients' access to community pharmacies," he warned.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze